ARTICLE | Clinical News
Idrabiotaparinux biotinylated idraparinux: Development discontinued
January 4, 2010 8:00 AM UTC
sanofi-aventis discontinued development of idrabiotaparinux to prevent thromboembolic events associated with atrial fibrillation (AF) after the compound did not show significant improvement compared t...